PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

Apr 16, 2014 | Posted by: roboblogger | Full story: Sys-Con Media

By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

•••
Enter and win $5000
•••

Protopic, Tacrolimus People Search

Addresses and phone numbers for FREE

•••